$PTN News
Last published 56m ago
- 56m agoPTNPalatin to Report First Quarter Fiscal Year 2027 ResultsPR NewswirePalatin Technologies, Inc. (Nasdaq: PTN) will announce its first quarter fiscal year 2027 operating results on Tuesday, November 17, 2026,...
- 1mo agoPTNFourth Quarter Fiscal Year 2026 Financial Teleconference and Webcast - PALATIN TECHNOLOGIES INCEarnings Call TranscriptsWelcome to Palatin's 4th Quarter and Fiscal Year-End 2026 Operating Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If
- 1mo agoPTNPalatin Reports Fiscal Year 2026 Financial Results and Provides Business UpdatePR NewswirePalatin Technologies, Inc. (Nasdaq: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor ("MCR") system,...
- 5mo agoPTNPalatin to Begin Trading on Nasdaq Stock ExchangePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development of novel therapeutics targeting ...
- 6mo agoPTNPalatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, ...
- 8mo agoPTNPalatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 12mo agoPTNFirst Quarter Fiscal Year 2026 Financial Teleconference and Webcast - PALATIN TECHNOLOGIES INCEarnings Call TranscriptsGreetings. Welcome to Palatine's first quarter fiscal year 2026 Operating Results Conference Call. At this time, all participants are on the listen-only mode. A question-and-answer session will follow the formal presenta
- 1y agoPTNPalatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment OptionPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
- 1y agoPTNPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticePR NewswirePalatin Technologies, Inc. (the "Company" or "Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...
- 1y agoPTNPalatin Technologies Announces Pricing of up to $23 Million Public OfferingPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
- 1y agoPTNPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative treatments targeting the melanocortin receptor...
- 1y agoPTNPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseasePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and TirzepatidePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Appeals NYSE American Notice of DelistingPR NewswirePalatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules...
- 1y agoPTNPalatin Technologies, Inc. Announces Receipt of NYSE American Notice of Delisting and Intention to AppealPR NewswirePalatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules...
- 1y agoPTNPalatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring MeetingPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity StudyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor DeficiencyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025PR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025,...
- 1y agoPTNPalatin Announces $4.7 Million Registered Direct Offering and Concurrent Private PlacementPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
- 1y agoPTNPalatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP TirzepatidePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Provides Update on Anticipated 2025 Corporate MilestonesPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic NephropathyPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Announces Exercise of Warrants for Approximately $3.4 Million Gross ProceedsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
- 1y agoPTNPalatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative ColitisPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 1y agoPTNPalatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call TranscriptEarnings Call Transcripts
- 1y agoPTNPalatin Reports First Quarter Fiscal Year 2025 Operating/Financial ResultsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024,...
- 2y agoPTNPalatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNInflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics SymposiumPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics SymposiumPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Receives Notice of Non-Compliance from NYSE AmericanPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Technologies, Inc. (PTN) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPTNPalatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin to Report Fourth Quarter and Fiscal Year End 2024 ResultsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1,...
- 2y agoPTNPalatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated MilestonesPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNFDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNFirst Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Announces Exercise of Warrants for Approximately $6.1 Million Gross ProceedsPR NewswirePalatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based...
- 2y agoPTNPalatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin Technologies, Inc. (PTN) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPTNPalatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate UpdatePR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024, before ...
- 2y agoPTNPalatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of ObesityPR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...
- 2y agoPTNPalatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024PR NewswirePalatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...